The European Medicines Agency’s introduction of email notifications in CTIS offers practical benefits that directly impact daily operations for trial sponsors, principal investigators, and regulatory professionals. The system provides three key advantages: customisable email subscriptions allow users to select specific trial milestones and events relevant to their involvement; role-based alerts ensure that sponsors, investigators, and regulatory staff receive targeted information appropriate to their responsibilities; and enhanced transparency is delivered without introducing delays to trial timelines or assessment processes. This targeted approach eliminates notification fatigue while ensuring stakeholders remain informed of critical developments. For organisations managing multiple trials across European jurisdictions, the ability to configure alerts by trial, amendment type, and regulatory decision category represents a substantial operational improvement. The implementation reflects the EMA’s commitment to leveraging digital infrastructure to support efficient, transparent clinical research governance while reducing administrative burdens on the research community. Stakeholders should explore customisation options to optimise their alert settings for maximum relevance. Read the full article on GMJ Newsroom.
Was this article helpful?
